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A carbapenem-resistant Alcaligenes faecalis strain was isolated from a surveillance swab of a service member injured in Afghani-
stan. The isolate was positive for blaNDM by real-time PCR. Species identification was reevaluated on three identification systems
but was inconclusive. Genome sequencing indicated that the closest relative was Acinetobacter schindleri and that blaNDM-1 was
carried on a plasmid that shared >99% identity with one identified in an Acinetobacter lwoffii isolate. The isolate also carried a
novel chromosomally encoded class D oxacillinase.
In response to global concerns over the spread of blaNDM (1–3),the Multidrug-resistant Organism Repository and Surveillance
Network (MRSN) implemented routine monthly screening for
this gene in all carbapenem-resistant Gram-negative organisms in
2010 (4). From this surveillance initiative, we previously described
the first incidence of blaNDM-1 in the U.S. military health care
system from a strain of Providencia stuartii, isolated from a local
Afghan national treated at a military facility in Afghanistan (5).
Timely feedback was provided to the submitting facility, which
resulted in increased surveillance and enhanced infection control
policies.
In June 2012, following a blast injury involving shrapnel in
Afghanistan, a 22-year-old male received cefazolin for routine
prophylaxis and was evacuated to the United States via Germany.
During that escalation of care, a routine groin surveillance swab
revealed mixed microbial flora. An isolate identified as Alcaligenes
faecalis using the BD Phoenix automated microbiology system
(BD Diagnostics Systems, Sparks, MD) displayed resistance to all
-lactam antibiotics tested (intermediate to ceftriaxone), includ-
ing the carbapenems and the monobactam aztreonam (Table 1). A
modified Hodge test (MHT) was negative for meropenem. For
ertapenem, the MHT was positive but the clover leaf-like growth
indentation of Escherichia coli ATCC 25922 was significantly re-
duced when grown with the test isolate, designated MRSN 10319,
compared to its growth alongside the blaKPC-positive control
strain Klebsiella pneumoniae ATCC BAA-1705. The isolate was
forwarded to the MRSN, a College of American Pathologists
(CAP)-certified laboratory, for further evaluation. The identifica-
tion was reevaluated using three automated identification sys-
tems: the Vitek 2 (bioMérieux, Durham, NC), the BD Phoenix,
and the Microscan WalkAway (Siemens Healthcare Diagnostics,
Inc., Deerfield, IL). The MRSN employs the three most common
automated instruments, as these instruments are used throughout
the Military Health System (MHS), and discrepancies between
their results have been noted (for a comprehensive review, see
reference 6). Both Vitek 2 and Microscan identified the organism
as Acinetobacter lwoffi, whereas the Phoenix was in agreement with
the initial identification of Alcaligenes faecalis. 16S rRNA sequenc-
ing was performed (7) and indicated that the isolate shared 99%
identity with Acinetobacter schindleri/Acinetobacter johnsonii.
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TABLE 1 Antibiotic susceptibility profile of A. schindleri MRSN 10319
Antibiotic
MIC (g/ml),
phenotypea Interpretation (g/ml)b
Arbekacin 0.25c NA
Amikacin 8, S 16, 32, 64
Ampicillin-sulbactam 16/8, R 8/4, 16/8, 32/16
Aztreonam 16d NA
Cefepime 16, R 8, 16, 32
Ceftazidime 16, R 8, 16, 32
Ceftriaxone 32, I 8, 16–32, 64
Ciprofloxacin 0.5, S 1, 2, 4
Colistin 0.25,e S 2, —, 4
Gentamicin 1, S 4, 8, 16
Imipenem 8, R 4, 8, 16
Levofloxacin 1, S 2, 4, 8
Meropenem 32, Rf 4, 8, 16
Piperacillin-tazobactam 64/4, R 16/4, 32/4–64/4, 128/4
Tetracycline 2, S 4, 8, 16
Tobramycin 1, S 4, 8, 16
Trimethoprim-sulfamethoxazole 0.5/9.5, S 2/38, —, 4/76
a MICs were determined using three automated systems (see the text), except for
arbekacin, colistin, and meropenem. All results were consistent across the three
instruments. The MICs and resulting interpretations are presented using the Phoenix
output for clarity. R, resistant; I, intermediate; S, susceptible.
b As recommended by the Clinical and Laboratory Standards Institute (CLSI) (18). NA,
no CLSI interpretative guidelines are available.
c MICs for arbekacin represent the average of three independent broth microdilution
assays as described previously (19).
d No CLSI interpretive guidelines for aztreonam are available for Acinetobacter species.
e Average of three independent Etest assays performed as described by the manufacturer
(bioMérieux). Etest results were consistent across replicates.
f As meropenem is not reported by the BD Phoenix Automated Microbiology System, MICs
were performed in triplicate by Etest as described by the manufacturer (bioMérieux). No
variation in Etest results was evidenced.
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Whole-genome sequencing (WGS) using an Ion Torrent PGM
(Ion Torrent Systems, Inc., Guilford, CT), which provided 87
coverage of the 16S rRNA gene, demonstrated 99.5% identity to
Acinetobacter schindleri 16S rRNA sequences deposited at GenBank
(Fig. 1A) (8). Phylogenetic analysis using the rpoB gene sequence
confirmed this identification (Fig. 1B).
MRSN 10319 was tested by real-time PCR for carbapenemase
genes (9) and was positive for blaNDM. The gene was found to
contain a single-nucleotide polymorphism (guanine to adenine)
at position 468 compared to blaNDM-1, resulting in a synonymous
mutation. The gene was located on a 47.3-kb plasmid that shared
99% identity with pNDM-BJ02, a plasmid identified in an iso-
late of Acinetobacter lwoffi cultured from the urine of a 62-year-old
female patient in Beijing in November 2010 (10). Hu and col-
leagues identified A. lwoffi by Vitek 2 but make no mention of the
16S rRNA sequence to verify this result. In accordance with the
discrepancies noted in this report, Dortet and colleagues have
noted that the Vitek 2 identifies rare species of Acinetobacter, in-
cluding A. schindleri, as A. lwoffi (11).
Plasmid pNDM-BJ02 has 46 open reading frames, and there is
no plasmid sequence in GenBank that shares more than 15% ho-
mology with it. Furthermore, the plasmid cannot be assigned to
any of the described incompatibility groups using the PCR repli-
con typing method developed by Carattoli and colleagues (12).
The plasmid harbors a type IV secretion system (T4SS) gene clus-
ter and a single copy of aphA6, which encodes resistance to some
aminoglycosides. However, MRSN 10319 was susceptible to all
aminoglycosides tested (Table 1). Sequence comparison to
pNDM-BJ02 suggests that the original promoter sequence for this
gene has been disrupted by an upstream transposition event, as
previously noted (10). Hu and colleagues demonstrated that the
plasmid had a relatively high transfer frequency (9.1  103 to 1.3 
102 per donor cell) to E. coli J53 Azir, suggesting that this plasmid
has a high propensity for horizontal transmission (10).
Analysis of the chromosomal sequence revealed just a single
locus with homology to known antibiotic resistance genes. This
locus encoded a class D oxacillinase that shares its closest homol-
ogy to the recently described blaOXA-237 gene (13) but has 18
amino acid differences and represents a novel blaOXA allele. There
is no evidence (i.e., no transposons or insertion sequences) in the
surrounding genetic environment to suggest horizontal acquisi-
tion of this gene. Based on the antibiotic profile of blaOXA-237 (13)
FIG 1 Dendrograms showing the relationship between A. schindleri MRSN 10319 and other Acinetobacter species based on (A) 16S rRNA and (B) rpoB gene
sequences. Acinetobacter species 16S rRNA and rpoB gene sequences were retrieved from GenBank (http://www.ncbi.nlm.nih.gov/pubmed; last accessed 23
August 2012) and aligned using MegAlign (DNASTAR, Madison, MI). Dendrograms based on the numbers of nucleotide changes were generated using the
MegAlign program (DNASTAR).
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and the lack of any other antibiotic resistance genes, including
other -lactams, aztreonam resistance in this strain is most likely
due to this class D oxacillinase. A complete analysis of the MRSN
10319 genome is ongoing and will provide further information.
This report highlights the limitations of automated identifica-
tion systems when working with unusual species. Commonly used
clinical laboratory identification systems do not include A. schin-
dleri or A. johnsonii on identification panels (manufacturer liter-
ature), which can lead to erroneous identification. Due to the high
correlation between blaNDM carriage and the Enterobacteriaceae,
surveillance strategies for this gene have primarily focused on this
group of bacteria. However, given the association of this gene with
highly promiscuous plasmids, as well as documented horizontal
dissemination of this gene, it is critical that surveillance efforts
continue to test all carbapenem-resistant Gram-negative organ-
isms for blaNDM. A number of good techniques exist for detecting
NDM-producing Enterobacteriaceae (14), but false-negative and
weakly positive results have been observed in this family with the
popular MHT (15, 16). Detection in Acinetobacter species remains
a challenge due to the potential failure of many techniques, in-
cluding the MHT and Etest MBL strip (17). Bonnin and colleagues
have suggested that for carbapenem-resistant Acinetobacter bau-
mannii, isolates should first be screened using EDTA inhibition-
based techniques, followed by further PCR-based techniques in a
reference laboratory (17). We suggest that the same method be
applied to all other carbapenem-resistant Acinetobacter species
isolated from clinical specimens.
Nucleotide sequence accession number. The novel blaOXA lo-
cus described in this study has been assigned the designation
blaOXA278 (http://www.lahey.org/studies/; last accessed March
2013), and the complete gene sequence has been deposited at
GenBank (accession number KC771279).
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